Mitchell Sinkler & Starr PA boosted its stake in shares of Pfizer, Inc. (NYSE:PFE) by 4.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 17,387 shares of the biopharmaceutical company’s stock after buying an additional 700 shares during the period. Mitchell Sinkler & Starr PA’s holdings in Pfizer were worth $584,000 at the end of the most recent quarter.
A number of other institutional investors have also recently bought and sold shares of PFE. Asset Planning Services Ltd. raised its position in Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 137 shares during the last quarter. D. Scott Neal Inc. raised its position in Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 504 shares during the last quarter. Orrstown Financial Services Inc. raised its position in Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 612 shares during the last quarter. Franklin Parlapiano Turner & Welch LLC purchased a new position in Pfizer during the first quarter valued at $121,000. Finally, Cascade Investment Advisors Inc. raised its position in Pfizer by 89.1% in the second quarter. Cascade Investment Advisors Inc. now owns 4,669 shares of the biopharmaceutical company’s stock valued at $157,000 after buying an additional 2,200 shares during the last quarter. Institutional investors own 69.94% of the company’s stock.
Shares of Pfizer, Inc. (PFE) traded down 0.5000% during midday trading on Thursday, reaching $33.1932. 4,021,864 shares of the company traded hands. The company’s 50 day moving average is $33.35 and its 200-day moving average is $33.37. Pfizer, Inc. has a 12 month low of $29.83 and a 12 month high of $35.38. The stock has a market capitalization of $197.41 billion, a price-to-earnings ratio of 24.2818 and a beta of 1.00.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. The company had revenue of $12.90 billion for the quarter, compared to analyst estimates of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The business’s quarterly revenue was down 1.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.64 earnings per share. Equities research analysts forecast that Pfizer, Inc. will post $2.56 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 1st. Stockholders of record on Friday, August 4th will be paid a dividend of $0.32 per share. The ex-dividend date is Wednesday, August 2nd. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.84%. Pfizer’s dividend payout ratio is currently 94.12%.
ILLEGAL ACTIVITY NOTICE: “Pfizer, Inc. (PFE) Position Increased by Mitchell Sinkler & Starr PA” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/08/17/pfizer-inc-pfe-position-increased-by-mitchell-sinkler-starr-pa.html.
Several equities analysts have weighed in on the stock. Citigroup Inc. lowered shares of Pfizer from a “neutral” rating to a “sell” rating and decreased their target price for the company from $38.00 to $31.00 in a report on Tuesday, May 16th. BidaskClub upgraded shares of Pfizer from a “strong sell” rating to a “sell” rating in a report on Saturday, August 5th. Jefferies Group LLC set a $35.00 target price on shares of Pfizer and gave the company a “neutral” rating in a report on Wednesday, August 2nd. BMO Capital Markets upgraded shares of Pfizer from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $33.00 to $37.00 in a report on Wednesday, August 2nd. Finally, Barclays PLC reiterated a “buy” rating and issued a $38.00 target price on shares of Pfizer in a report on Wednesday, May 3rd. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $37.61.
In other news, CEO Ian C. Read sold 96,950 shares of Pfizer stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $34.00, for a total transaction of $3,296,300.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Alexander R. Mackenzie sold 15,000 shares of Pfizer stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $33.50, for a total transaction of $502,500.00. Following the sale, the insider now owns 151,474 shares in the company, valued at approximately $5,074,379. The disclosure for this sale can be found here. Company insiders own 0.06% of the company’s stock.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).
What are top analysts saying about Pfizer Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pfizer Inc. and related companies.